Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced ...
Organoids have now evolved beyond simple experimental models to become next-generation biological platforms that precisely replicate human organ ...
Researchers at Mount Sinai launch a new AI platform to match more cancer patients with clinical trials, aiming to expand ...
Charles River Laboratories International, Inc. today announced two planned acquisitions of K.F. (Cambodia) Ltd. and PathoQuest SAS; the addition of Dr. Namandjé N. Bumpus as Chief Scientific and ...
SurvivorNet on MSN
Cancer patients are living longer — a closer look at the treatments driving this progress
New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...
The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue ...
Routine newborn screening (NBS) has transformed early disease detection. However, traditional biochemical tests limit the range of conditions that can be identified at birth. Next-generation ...
NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform. Read why ...
Ongoing combination of Twist NGS library preparation kits with firefly will continue to expand SPT Labtech’s portfolio of ...
FDA-cleared EsoGuard/EsoCheck screening, Medicare coverage catalysts, Q3 results, VA contract and risks. Click here to read.
Located on the Buffalo Niagara Medical Campus and the first next-generation sequencing service provider in the region, UB's Genomics and Bioinformatics Core Facility provides high-quality services ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results